For more than 50 years, federal and state lawmakers have been fighting “price gouging” in the prescription-drug industry. Read more here.
Policy & Price
‘We don’t apologize for being highly profitable until our patents run out,” says the man seated in the barest office of any corporate leader I’ve visited. Read more here.
he National Institutes of Health will get a $2 billion funding boost over the next five months, under a bipartisan spending deal reached late Sunday night in Congress. Read more here.
The nation’s top health official made an appeal Monday morning for the preservation of the Affordable Care Act, insisting that the sprawling health-care law that President-elect Donald Trump is vowing to eliminate is “now woven into the fabric of our nation.” Read more here.
Americans have expressed outrage at drug companies for raising prices on products like EpiPen, the severe allergy treatment needed by thousands of children, and Daraprim, a rarely used but essential drug to treat a parasitic infection. Read more here.
Total orphan drug spending represented approximately 1 percent of total U.S. health care spending, according to the authors. Rising concerns about spending on prescription drugs that treat rare diseases are not justified, according to a new analysis in the journal Health Affairs. “We wanted to focus on the true impact of orphan drugs,” said Victoria […]
By Tomas J. Philipson and Jason Shafrin New value frameworks in health care have emerged due to increasing cost pressures. Although value frameworks can be useful tools, they should be used to complement the patient-physician treatment decision-making process, rather than substitute for it. This entails getting away from “one size fits all” rules as well […]
Price increases continue despite pushback from insurers, U.S. lawmakers By JOSEPH WALKER | July 14, 2016 5:30 a.m. Pharmaceutical companies’ power to raise prices is firmly intact despite pushback from health insurers, scrutiny by U.S. lawmakers and anxiety about rising prescription drug spending. More than two-thirds of the 20 largestpharmaceutical companies said price increases boosted sales of […]
Chimeric antigen receptor T cell (CAR-T) therapy has indisputably become one of the industry’s hottest topics and the next 18 months could see the first CAR-T drugs filed for US approval. But behind the excitement for all things CAR-T lie a number of obstacles in their path to approval. In its second deep-dive into the […]
Government action might not be needed to pressure prices on some drugs A comprehensive government crackdown on high drug prices isn’t likely soon. Still, investors shouldn’t let their guard down. Biotech and pharmaceutical stocks have struggled since last summer when the controversy erupted into a big political issue. Last week’s congressional hearing on the […]
A $471 million UBS venture fund aims to generate annual returns “north of 10 percent” for its European and Asian investors by financing new cancer drugs, helping speed them from the lab to the point where drug companies buy their rights. Mark Haefele, global chief investment officer at the Swiss bank’s wealth management unit, said […]
Today the U.S. Food and Drug Administration announced a comprehensive policy framework for the development and oversight of regenerative medicine products, including novel cellular therapies. Read more here.
What does it really cost to bring a drug to market? Read more here.
No factor defines success and failure for a drug company more than this: Companies that invent more, better drugs at a lower cost do better than those that hemorrhage cash but never get an important product to market. Read more here.
The controversy over Obamacare and now the raucous debate over its possible repeal and replacement have taken center stage recently in American politics. Read more here.
In the early days of his administration, President Trump did not hesitate to bash the drug industry. Read more here.
The new commissioner of the Food and Drug Administration plans a multifaceted effort to restrain high prescription-drug prices, centered on speeding cheaper generic medicines onto the U.S. market. Read more here.
A transformation of the delivery of health care may be an enduring legacy for the president, even as Republicans plan to repeal the Affordable Care Act. Read more here.
An industry-friendly commissioner seems to be coming to the Food and Drug Administration. While he is favored by many executives, not all drug makers will be happy once he gets on the job. Read more here.
Levi Collazo, a biology major at Southwestern Oklahoma State University, has cystic fibrosis (CF). Read more here.
Call it the Pfizer put. The giant pharmaceutical company sold €4 billion ($4.22 billion) in bonds this week, paying a yield of almost nothing.The ease and low cost of Pfizer’s borrowing shows that it or any of its major rivals could easily fund the acquisition of almost any biotech. Read more here.